U.S. Markets closed
  • S&P Futures

    4,117.25
    -9.25 (-0.22%)
     
  • Dow Futures

    33,661.00
    -42.00 (-0.12%)
     
  • Nasdaq Futures

    13,725.75
    -68.50 (-0.50%)
     
  • Russell 2000 Futures

    2,180.90
    -3.10 (-0.14%)
     
  • Crude Oil

    62.61
    +0.17 (+0.27%)
     
  • Gold

    1,782.90
    +4.50 (+0.25%)
     
  • Silver

    25.94
    +0.10 (+0.39%)
     
  • EUR/USD

    1.2037
    -0.0004 (-0.0361%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • Vix

    18.68
    +1.39 (+8.04%)
     
  • GBP/USD

    1.3934
    -0.0003 (-0.0237%)
     
  • USD/JPY

    107.9620
    -0.1080 (-0.0999%)
     
  • BTC-USD

    56,094.20
    +1,297.21 (+2.37%)
     
  • CMC Crypto 200

    1,286.73
    +52.31 (+4.24%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    28,462.20
    -638.18 (-2.19%)
     

Should You Buy Amneal (AMRX) Ahead of Earnings?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Investors are always looking for stocks that are poised to beat at earnings season and Amneal Pharmaceuticals, Inc. AMRX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Amneal is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for AMRX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently higher than the broader Zacks Consensus Estimate of 13 cents per share. This suggests that analysts have very recently bumped up their estimates for AMRX, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season.

AMNEAL PHARMACEUTICALS, INC. Price and EPS Surprise

AMNEAL PHARMACEUTICALS, INC. Price and EPS Surprise
AMNEAL PHARMACEUTICALS, INC. Price and EPS Surprise

AMNEAL PHARMACEUTICALS, INC. price-eps-surprise | AMNEAL PHARMACEUTICALS, INC. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that AMRX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Amneal, and that a beat might be in the cards for the upcoming report.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.